NCT04895930View on ClinicalTrials.gov

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Furmonertinib

80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).

DRUG

Anlotinib

10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).

Trial Locations (1)

200000

RECRUITING

Shanghai Chest Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Allist Pharmaceuticals, Inc.

INDUSTRY

lead

Shanghai Chest Hospital

OTHER